ResMed Inc. (RMD)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EST
After hours:
| Previous close | 152.57 |
| Open | 151.95 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's range | 151.95 - 155.99 |
| 52-week range | 132.24 - 243.52 |
| Volume | |
| Avg. volume | 1,610,853 |
| Market cap | 22.899B |
| Beta (5Y monthly) | 0.52 |
| PE ratio (TTM) | 25.31 |
| EPS (TTM) | 6.15 |
| Earnings date | 24 Jan 2024 - 29 Jan 2024 |
| Forward dividend & yield | 1.92 (1.23%) |
| Ex-dividend date | 08 Nov 2023 |
| 1y target est | 179.00 |
Simply Wall St.Investors Shouldn't Overlook The Favourable Returns On Capital At ResMed (NYSE:RMD)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
- Simply Wall St.
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Key Insights ResMed's Annual General Meeting to take place on 16th of November Salary of US$1.13m is part of CEO Mick...
GlobeNewswireResMed Adopts New Operating Model to Accelerate Long-term Growth
Justin Leong appointed Chief Product Officer, effective immediately.Katrin Pucknat appointed Chief Marketing Officer, effective immediately.Mike Fliss appointed Chief Revenue Officer, effective immediately.Rob Douglas, President and Chief Operating Officer, to retire January 1, 2024. SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced a new operating model to accelerate long-term growth. The new operating model introduces dedicated leadership in Product, Rev
© 2023 Yahoo. All rights reserved.